Literature DB >> 18706658

Effects of mirtazapine on dehydroepiandrosterone-sulfate and cortisol plasma concentrations in depressed patients.

Cornelius Schüle1, Thomas C Baghai, Daniela Eser, Markus Schwarz, Brigitta Bondy, Rainer Rupprecht.   

Abstract

BACKGROUND: Among the neuroactive steroids, dehydroepiandrosterone sulfate (DHEA-S) is at least in part produced in the adrenal gland and is therefore under the control of the hypothalamic-pituitary-adrenocortical (HPA)-system. In the present study, the impact of mirtazapine on DHEA-S and cortisol (COR) levels was investigated in relation to clinical response in depressed patients.
METHODS: A total of 23 inpatients suffering from a major depressive episode (DSM-IV criteria) underwent 5-week treatment with mirtazapine (45 mg/day). Plasma samples were taken weekly at 0800 h and quantified for COR and DHEA-S levels.
RESULTS: Mirtazapine significantly reduced both COR and DHEA-S concentrations, but had no impact on the COR/DHEA-S ratio. The percentage decrease of DHEA-S, but not that of COR was significantly and positively correlated with the percentage reduction in the sum score of the Hamilton Depression Rating Scale at week 5, suggesting a relationship between DHEA-S reduction and clinical efficacy of mirtazapine. There was a significant positive correlation between the decline in COR and DHEA-S levels.
CONCLUSIONS: Apparently, the decrease in COR and DHEA-S concentrations conjointly reflects an attenuating impact of mirtazapine on HPA axis activity, thereby decreasing the adrenal secretion of COR and DHEA-S.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18706658     DOI: 10.1016/j.jpsychires.2008.07.003

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  5 in total

1.  Fluvoxamine enhances prefrontal dopaminergic neurotransmission in adrenalectomized/castrated mice via both 5-HT reuptake inhibition and σ(1) receptor activation.

Authors:  Yukio Ago; Koji Yano; Naoki Hiramatsu; Kazuhiro Takuma; Toshio Matsuda
Journal:  Psychopharmacology (Berl)       Date:  2011-04-13       Impact factor: 4.530

2.  Higher serum DHEA concentrations before and after SSRI treatment are associated with remission of major depression.

Authors:  Christina M Hough; Daniel Lindqvist; Elissa S Epel; Molly St Denis; Victor I Reus; F Saverio Bersani; Rebecca Rosser; Laura Mahan; Heather M Burke; Owen M Wolkowitz; Synthia H Mellon
Journal:  Psychoneuroendocrinology       Date:  2016-12-05       Impact factor: 4.905

3.  Neuroimmune endocrine effects of antidepressants.

Authors:  Marco Antonioli; Joanna Rybka; Livia A Carvalho
Journal:  Neuropsychiatr Dis Treat       Date:  2012-02-07       Impact factor: 2.570

4.  Effect of selective serotonin reuptake inhibitors and immunomodulator on cytokines levels: an alternative therapy for patients with major depressive disorder.

Authors:  María Eugenia Hernandez; Danelia Mendieta; Mayra Pérez-Tapia; Rafael Bojalil; Iris Estrada-Garcia; Sergio Estrada-Parra; Lenin Pavón
Journal:  Clin Dev Immunol       Date:  2013-11-17

5.  Role of insulin-like growth factor 1, sex and corticosteroid hormones in male major depressive disorder.

Authors:  Hiroshi Arinami; Yutaro Suzuki; Misuzu Tajiri; Nobuto Tsuneyama; Toshiyuki Someya
Journal:  BMC Psychiatry       Date:  2021-03-17       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.